Christopher Sadler

Pharmaron

Pharmaron (Stock Code: 300759.SZ/3759.HK) is a premier R&D service provider for the life sciences industry. Founded in 2004, Pharmaron has invested in its people and facilities, and established a broad spectrum of research, development and manufacturing service capabilities throughout the entire drug discovery, preclinical and clinical development process across multiple therapeutic modalities, including small molecules, biologics and CGT products. With over 17,000 employees and operations in China, the U.S., and the U.K., Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China. Pharmaron is a contract research organization (CRO). Services: * Synthetic, medicinal and analytical chemistry services * Biology services * DMPK services * Pharmacology services * Drug safety assessment services * Radiochemistry and isotopically labelled metabolism services * Chemical & pharmaceutical development services * Clinical development services www.pharmaron.com CRO - Contract Research Organization Library Synthesis CADD Bioorganic Chemistry Discovery Process Chemistry Radiolabelled Chemical Synthesis ChemInformatics in vitro Biology in vitro Screening Structural Biology in vivo Pharmacology Animal Disease Models ex vivo Pharmacology Biomarkers in vitro ADME in vivo PK PKPD QA Regulatory Affairs Discovery Biologics Process Chemistry API Manufacturing Material Science Formulation Development Drug Product Manufacturing Toxicology Safety Pharmacology Genetic Toxicology DART Pathology Immunotoxicity Bioanalytical 14C / Carbon-14 Radiosynthesis 3H / Tritium Radiosynthesis QWBA mARG Clinical AME Mass Balance Metabolite Profiling Microdosing Phase 0 Absolute Bioavailability DDI First-in-Human (FIH) Thorough QT(TQT) Ethnobridging